Previous 10 | Next 10 |
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE ® net product sales of $21.3 million and REZLIDHIA ® net product sales of $2.6...
Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , July 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will re...
2023-07-17 11:49:11 ET Interested in discovering the top penny stocks to invest in? You’re certainly not the only one. Capitalizing on the stock market’s opportunities is the key to this process. However, the precise method of execution varies based on each individual ...
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML PR Newswire Durable remissions observed in patients relapsed or refractory to prior venetoclax-based regimens Data featured in a poster pre...
2023-06-06 15:26:48 ET Rigel Pharmaceuticals ( NASDAQ: RIGL ) added ~9% on Tuesday after announcing that the medical journal Blood Advances published data supporting Rezlidhia (olutasidenib), its FDA-approved treatment for acute myeloid leukemia (AML). In December, Rigel ( ...
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances PR Newswire Review article examines the preclinical and clinical development, and the role of olutasidenib in the m IDH1 AML treatment landscape. Authors conclude, "The approval of olut...
Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting PR Newswire SOUTH SAN FRANCISCO, Calif. , June 1, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster...
Rigel to Present at the Jefferies 2023 Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , May 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief ...
2023-05-26 02:03:10 ET Summary Tavalisse's robust growth in Q1, with record shipments and a 23% YoY increase, positions it as a preferred treatment for third-line patients, potentially expanding its market share. Rezlidhia, since its launch in December, demonstrated market accepta...
2023-05-19 08:20:29 ET Lucy Scientific Discovery ( LSDI ) +43% . Farfetch Limited ( FTCH ) +22% Q1 earnings call release Greenland Technologies Holding ( GTEC ) +14% Q1 earnings call release Nabriva Therapeutics ( NBRV ) +11% . G...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...